Altimmune, Inc. (ALT) Misses Q4 EPS by 10c

Altimmune, Inc. (NASDAQ: ALT) reported Q4 EPS of ($0.54), $0.10 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $2.14 thousand.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• The free USDA tool that tracks egg prices at $0.62/dozen before your data vendor does
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss